您当前的位置: 首页 > 最新研究

最新研究共计 2,612 条信息

      全选  导出

1 Medicalxpress,1月10日,Even symptom-free, people with Omicron are much more likely to spread COVID, say studies 2022-01-17

Researchers say they have uncovered aclue to why the Omicron variant spreads COVID-19 so much more rapidly than its predecessors. People who are infected but have no symptoms are still far more likely to infect others than they would have been with earlier variants,the data shows. 查看详细>>

来源: 点击量:80

2 Medicalxpress,1月10日,Researchers use artificial intelligence to guide the search for the next SARS-like virus 2022-01-17

An international research team led by scientists at Georgetown University have demonstrated the power of artificial intelligence to predict which viruses could infect humans like SARS-CoV-2,the virus that led to the COVID-19 pandemic which animals host them,and where they could emerge. 查看详细>>

来源: 点击量:75

3 Medicalxpress,1月7日,Omicron resistant to most monoclonal antibodies but neutralized by a booster dose 2022-01-17

The Omicron variant was detected for the first time in South Africa in November 2021 and has since spread to many countries.It is expected to become the dominant variant within afew weeks or months.Initial epidemiological studies show that the Omicron variant is more transmissible than the currently dominant virus(the Delta variant).It is capable of spreading to individuals who have received two vaccine doses and to previously infected individuals. Scientists from the Institut Pasteur and the Vaccine Research Institute,in collaboration with KU Leuven(Leuven,Belgium),Orléans Regional Hospital,Hôpital Européen Georges Pompidou(AP-HP),Inserm and the CNRS,studied the sensitivity of the Omicron variant to monoclonal antibodies used in clinical practice to prevent severe forms of the disease in people at risk,as well as to antibodies in the blood of individuals previously infected with SARS-CoV-2 or vaccinated.They compared this sensitivity with that of the Delta variant.The scientists demonstrated that Omicron is much less sensitive to neutralizing antibodies than Delta. The scientists then analyzed the blood of people who had received two doses of the Pfizer or AstraZeneca vaccine.Five months after vaccination,the antibodies in the blood were no longer capable of neutralizing Omicron.This loss of efficacy was also observed in individuals who had been infected with SARS-CoV-2 within the past 12 months.Administering abooster dose of the Pfizer vaccine or asingle vaccine dose in previously infected individuals led to asignificant increase in antibody levels that was sufficient to neutralize Omicron.Omicron is therefore much less sensitive to the anti-SARS-CoV-2 antibodies currently used in clinical practice or obtained after two vaccine doses. The study was published as apreprint on the bioRxiv website on December 15,2021 and in Nature on Dec 23,2021 Initial epidemiological studies demonstrate that the Omicron variant is more transmissible than the Delta variant.The Omicron variant's biological characteristics are still relatively unknown.It has more than 32 mutations in the spike protein compared with the first SARS-CoV-2 and was designated as avariant of concern by WHO on November 26,2021. In South Africa,the Omicron variant replaced the other viruses within afew weeks and led to asharp increase in the number of cases diagnosed.Analyses in various countries indicate that the doubling time for cases is approximately 2to 4days.Omicron has been detected in dozens of countries,including France and became dominant by the end of 2021. 查看详细>>

来源: 点击量:75

4 Science,1月6日,Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry 2022-01-17

Understanding broadly neutralizing sarbecovirus antibody responses is key to developing countermeasures against SARS-CoV-2 variants and future zoonotic sarbecoviruses.We describe the isolation and characterization of ahuman monoclonal antibody,designated S2K146,that broadly neutralizes viruses belonging to SARS-CoV-and SARS-CoV-2-related sarbecovirus clades which use ACE2 as an entry receptor.Structural and functional studies show that most of the virus residues that directly bind S2K146 are also involved in binding to ACE2.This allows the antibody to potently inhibit receptor attachment.S2K146 protects against SARS-CoV-2 Beta challenge in hamsters and viral passaging experiments reveal ahigh barrier for emergence of escape mutants,making it agood candidate for clinical development.The conserved ACE2-binding residues present asite of vulnerability that might be leveraged for developing vaccines eliciting broad sarbecovirus immunity. 查看详细>>

来源: 点击量:36

版权所有@2017中国科学院文献情报中心

制作维护:中国科学院文献情报中心信息系统部地址:北京中关村北四环西路33号邮政编号:100190